SIGLEC11: Sialic Acid-Binding Ig-Like Lectin 11 – Neuroimmune Signaling and Disease Relevance
A comprehensive biomedical overview of SIGLEC11, including gene structure, expression, function, and clinical significance.
Gene Information Card
| Symbol | SIGLEC11 |
|---|---|
| Full Name | sialic acid binding Ig like lectin 11 |
| Gene Type | protein coding |
| Chromosomal Location | 19q13.33 |
| NCBI Gene ID | 114132 ncbi.nlm.nih.gov/gene/114132 |
| Ensembl ID | ENSG00000182269 |
| UniProt ID | Q96RL6 |
| OMIM ID | 612101 |
| HGNC ID | 30874 |
| Aliases | SIGLEC-11, Siglec11, sialic acid binding Ig-like lectin 11 |
Description
SIGLEC11 (sialic acid binding Ig-like lectin 11) is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It is a transmembrane receptor that recognizes sialic acid-containing glycans. SIGLEC11 is predominantly expressed in human microglia and plays a role in neuroimmune regulation, including inhibition of inflammatory responses. It has been implicated in several neurological and psychiatric conditions, as well as in cancer biology.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Schizophrenia | Altered SIGLEC11 expression in microglia may affect synaptic pruning and neuroinflammation, contributing to schizophrenia pathophysiology. | Case-control studies show differential expression in brain tissue (e.g., PMID: 25816173). |
| Alzheimer's disease | SIGLEC11-mediated inhibition of microglial phagocytosis may impair clearance of amyloid-beta plaques. | Expression changes observed in AD brains; functional studies in vitro (e.g., PMID: 27466428). |
| Cancer (various) | SIGLEC11 expression on tumor-associated macrophages may modulate tumor immune evasion via sialic acid interactions. | Immunohistochemistry and transcriptomic data from COSMIC and literature (e.g., PMID: 29217573). |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | Not available (nTPM not provided) | High expression in microglia |
| Lung | Not available | Low expression |
| Spleen | Not available | Low expression |
| Blood | Not available | Low expression in leukocytes |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Microglia (primary) | Not available | High expression; key cell type |
| Macrophages (monocyte-derived) | Not available | Moderate expression |
| HEK293 (transfected) | Not available | Used for functional assays |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| rs4985556 | SNV (missense) | Minor allele frequency ~0.1-0.2 in some populations | May affect ligand binding; clinical significance uncertain |
| rs2075797 | SNV (intronic) | Common | No known functional effect |
| COSM123456 (example) | Somatic mutation in cancer | Rare | Potential impact on protein function; not well characterized |
Mutation functional classification
Loss of Function (LOF)
Loss-of-function mutations in SIGLEC11 have not been extensively reported; however, reduced expression or function may impair anti-inflammatory signaling in microglia.
Gain of Function (GOF)
Gain-of-function mutations are not well documented; overexpression in certain cancers may enhance immune evasion.
Dominant Negative (DN)
No dominant-negative mutations have been described for SIGLEC11.
View complete mutation data：
Gene Ontology (GO)
| • carbohydrate binding | • protein binding |
| • sialic acid binding | • cell surface receptor signaling pathway |
| • inflammatory response | • negative regulation of inflammatory response |
| • microglia development | • synaptic pruning |
Pathways
• Sialic acid metabolism
• Immune response regulation
• Microglial signaling
• Neuroinflammation
Protein Summary
SIGLEC11 is a type I transmembrane protein with an extracellular N-terminal V-set domain that binds sialic acid, followed by two C2-set domains. It contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic tail, which recruit phosphatases to dampen immune activation. In the brain, SIGLEC11 is selectively expressed in microglia and contributes to maintaining an anti-inflammatory environment. It also has roles in cell-cell interactions and may be involved in tumor immune evasion.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SIGLEC11 Knockout HEK293 Cell Line | EDJ-KQ7439 | Human | 114132 | Details Get a Quote |
| SIGLEC11 Knockout HeLa Cell Line | EDJ-KQ57918 | Human | 114132 | Details Get a Quote |
| SIGLEC11 Knockout A-549 Cell Line | EDJ-KQ66408 | Human | 114132 | Details Get a Quote |
| SIGLEC11 Knockout HCT 116 Cell Line | EDJ-KQ74835 | Human | 114132 | Details Get a Quote |
